Medizinisches Versorgungszentrum Taunus GmbH
- Address
- Zeppelinstrasse 24, 61352 Bad Homburg, Germany
Medizinisches Versorgungszentrum Taunus GmbH - Thoracic Oncology Research
Medizinisches Versorgungszentrum Taunus GmbH is a specialized medical care center actively engaged in advanced clinical research for lung cancer treatment. The center demonstrates particular expertise in comparative effectiveness studies evaluating novel immunotherapy combinations for patients with metastatic lung adenocarcinoma, focusing on precision medicine approaches based on specific biomarker profiles.
- Metastatic TTF-1 negative lung adenocarcinoma treatment optimization
- Immunotherapy combination regimens comparing atezolizumab and pembrolizumab protocols
- Platinum-based chemotherapy combinations with targeted biologics
The center's research portfolio emphasizes comparative survival outcomes in advanced non-small cell lung cancer, particularly investigating the efficacy of checkpoint inhibitor combinations with chemotherapy. Their focus on TTF-1 biomarker-negative adenocarcinomas represents an important contribution to understanding treatment responses in this distinct patient population, ultimately working to improve therapeutic strategies for advanced stage lung cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinisches Versorgungszentrum Taunus GmbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel Versus Pembrolizumab, Platinum, and Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma | Charite Universitaetsmedizin Berlin KöR | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2023-09-15 | 2023-09-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.